| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/15/2011 | US20110224138 Methods for treating pain induced by injuries and diseases of an articular joint |
| 09/15/2011 | US20110224137 Inhibitors of diacylglycerol acyltransferase |
| 09/15/2011 | US20110224136 Inhibitors of diacylglycerol acyltransferase |
| 09/15/2011 | US20110224135 Use of conkunitzin-s1 for the modulation of glucose-induced insulin secretion |
| 09/15/2011 | US20110224134 Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors |
| 09/15/2011 | US20110224133 Highly Potent Peptides To Control Cancer And Neurodegenerative Diseases |
| 09/15/2011 | US20110224132 Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases |
| 09/15/2011 | US20110224130 Cross-linked glycopeptide-cephalosporin antibiotics |
| 09/15/2011 | US20110224129 Lipopeptide Compounds and Their Use |
| 09/15/2011 | US20110224128 Methods and compositions for treatment of muscular dystrophy |
| 09/15/2011 | US20110223262 Method of Enhancing Biological Activity of Plant Extracts |
| 09/15/2011 | US20110223255 Implantable products comprising nanoparticles |
| 09/15/2011 | US20110223254 Functionalized diphenolics and absorbable polymers therefrom |
| 09/15/2011 | US20110223240 Compounds for reversing and inhibiting protein aggregation, and methods for making and using them |
| 09/15/2011 | US20110223233 Microfabricated nanopore device for sustained release of therapeutic agent |
| 09/15/2011 | US20110223230 Hydrogel formulations |
| 09/15/2011 | US20110223225 Solid oil powders |
| 09/15/2011 | US20110223217 Block copolymers and uses thereof |
| 09/15/2011 | US20110223216 Nanoparticles and Porous Particles and Methods of Making the Same |
| 09/15/2011 | US20110223208 Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| 09/15/2011 | US20110223204 Treatment of pain with gap junction modulation compounds |
| 09/15/2011 | US20110223203 Nanocluster compositions and methods |
| 09/15/2011 | US20110223202 Cationic core-shell peptide nonoparticles |
| 09/15/2011 | US20110223189 Agent for treating leishmania infections |
| 09/15/2011 | US20110223184 Dkk2 protein and use thereof |
| 09/15/2011 | US20110223181 Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium |
| 09/15/2011 | US20110223177 Treatment of fibrotic eye disorders |
| 09/15/2011 | US20110223174 Nontypeable Haemophilus Influenzae Virulence Factors |
| 09/15/2011 | US20110223173 Botulinum Neurotoxin A Receptor and the Use Thereof |
| 09/15/2011 | US20110223172 Soluble Forms of Hendra and Nipah Virus F Glycoprotein and Uses Thereof |
| 09/15/2011 | US20110223167 Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| 09/15/2011 | US20110223164 Binding domain-immunoglobulin fusion proteins |
| 09/15/2011 | US20110223162 Targeting pax2 for the treatment of breast cancer |
| 09/15/2011 | US20110223158 Association of levels of hdl-cholesterol apolipoprotein ciii with the risk of coronary heart disease and cardiovascular events |
| 09/15/2011 | US20110223156 Reversible gel protein formulation |
| 09/15/2011 | US20110223153 Modified silk films containing glycerol |
| 09/15/2011 | US20110223151 Conjugated proteins with prolonged in vivo efficacy |
| 09/15/2011 | US20110223150 Neutraceutical-Based Topical Anxiolytic Agent and Method of Use |
| 09/15/2011 | US20110223149 Peptidomimetic macrocycles |
| 09/15/2011 | US20110223148 Therapeutic/prophylactic agent for prostate cancer |
| 09/15/2011 | US20110223147 Lysosomal targeting peptides and uses thereof |
| 09/15/2011 | US20110223142 Methods and compositions for soft tissue repair |
| 09/15/2011 | US20110223138 Mesenchymal stem cells that express increased amounts of anti-apoptotic proteins |
| 09/15/2011 | US20110223136 Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor |
| 09/15/2011 | US20110223134 Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
| 09/15/2011 | US20110223133 Therapeutic agent for hematopoietic tumors |
| 09/15/2011 | US20110223132 Isothiazoloquinolones and related compounds as anti-infective agents |
| 09/15/2011 | US20110223131 Antiviral compounds |
| 09/15/2011 | US20110223130 USES OF IL-174 ANTAGONISTS FOR INHIBITING A Th2 IMMUNE RESPONSE |
| 09/15/2011 | US20110223129 Chimeric immunoreceptor useful in treating human cancers |
| 09/15/2011 | US20110223128 Regulation of microvasculature occlusion |
| 09/15/2011 | US20110223108 Glucagon-like peptide-2 and its therapeutic use |
| 09/15/2011 | US20110223102 Multimodality agents for tumor imaging and therapy |
| 09/15/2011 | CA2792910A1 Hjurp peptides and vaccines including the same |
| 09/15/2011 | CA2792862A1 Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| 09/15/2011 | CA2792727A1 Therapy for influenza like illness |
| 09/15/2011 | CA2792674A1 Peptide compounds that can be used as antibacterial agents |
| 09/15/2011 | CA2791741A1 Modulating aquaporins with relaxin |
| 09/15/2011 | CA2791732A1 Bridged lipoglycopeptides that potentiate the activity of beta-lactam antibacterials |
| 09/15/2011 | CA2789533A1 Process, tube and device for the preparation of wound healant composition |
| 09/14/2011 | EP2365097A1 Nucleic acid probe-based assays for prokaryotic and eukaryotic organisms |
| 09/14/2011 | EP2365094A1 Antisense modulation of PTP1B expression |
| 09/14/2011 | EP2365091A1 Method of screening for HtrA protease inhibitors useful for prophylaxis and therapy of a bacterial infection |
| 09/14/2011 | EP2365085A1 Growth hormone fusion protein |
| 09/14/2011 | EP2365081A2 13 Transmembrane protein expressed in prostate cancer |
| 09/14/2011 | EP2365004A2 Membrane associated tumor endothelium markers |
| 09/14/2011 | EP2364997A2 Polypeptide variants with altered effector function |
| 09/14/2011 | EP2364995A1 Conjugation product |
| 09/14/2011 | EP2364994A1 Purfied primate CTLA-8 antigens and related reagents |
| 09/14/2011 | EP2364990A1 Modulators of pharmacological agents |
| 09/14/2011 | EP2364734A1 Multi-component biological transport systems |
| 09/14/2011 | EP2364731A2 Methods of administering anti-TNFalpha antibodies |
| 09/14/2011 | EP2364727A2 Molecular antigen array |
| 09/14/2011 | EP2364719A1 Prevention and treatment of amyloidogenic diseases |
| 09/14/2011 | EP2364718A1 Enzyme treatment of foodstuffs for celiac sprue |
| 09/14/2011 | EP2364717A1 Control of blood glucose in diabetes treatment using pulmonarily administered insulin in combination with basal insulin |
| 09/14/2011 | EP2364716A2 Compositions and methods for the treatment of natural killer cell related diseases |
| 09/14/2011 | EP2364696A1 Formulations for delivery via pressurised metered dose inhalers |
| 09/14/2011 | EP2364691A1 VEGF antagonist formulations suitable for intravitreal administration |
| 09/14/2011 | EP2364690A1 Orally administrable pharmaceutical pellet of epidermal growth factor |
| 09/14/2011 | EP2364324A1 Use of inhibitors of plac8 activity for the modulation of adipogenesis |
| 09/14/2011 | EP2364310A2 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication |
| 09/14/2011 | EP2364309A2 New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
| 09/14/2011 | EP2364168A1 Extended length botulinum toxin formulation for human or mammalian use |
| 09/14/2011 | EP2364166A1 Suppression of cancer |
| 09/14/2011 | EP2364165A2 Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents |
| 09/14/2011 | EP2364164A1 Method and composition for enhancement of male erectile function |
| 09/14/2011 | EP2364163A1 Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer |
| 09/14/2011 | EP2364162A2 Compositions and methods for diagnosing and treating b-cll |
| 09/14/2011 | EP2364161A2 Compositions containing satiogens and methods of use |
| 09/14/2011 | EP2364160A1 Compositions containing interleukin-1 and peptides |
| 09/14/2011 | EP2364159A1 Deuterated macrocyclic inhibitors of viral ns3 protease |
| 09/14/2011 | EP2301580A9 Container holding anti-VEGF antibodies |
| 09/14/2011 | EP2275441A9 High affinity HIV T cell receptors |
| 09/14/2011 | EP2125873B1 Tau peptide mimetic for use in treating neurodegenerative disorders |
| 09/14/2011 | EP2046826B1 Exendin fusion proteins |
| 09/14/2011 | EP2007794B1 Lysobactin amides |
| 09/14/2011 | EP1940348B1 A composition comprising a coupled enzyme system |
| 09/14/2011 | EP1912997B1 Macrocyclic inhibitors of hepatitis c virus |
| 09/14/2011 | EP1910407B1 Mutated pseudomonas exotoxins with reduced antigenicity |